We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pfizer/BioNTech Could File for Full Vaccine Approval in April, with Trial Showing High Efficacy After Six Months

Pfizer/BioNTech Could File for Full Vaccine Approval in April, with Trial Showing High Efficacy After Six Months

April 5, 2021

Pfizer and BioNTech have accrued the data necessary to submit a biologics license application (BLA) for their COVID-19 vaccine and are seeking full approval as soon as this month, following a recent analysis from their phase 3 trial showing the vaccine held 91.3 percent efficacy up to six months after the second dose.

According to the two drugmakers, an analysis of 927 confirmed symptomatic COVID-19 cases seen in the late-stage study through March 13 showed the continued effectiveness against the virus up to six months after the second dose. Of the confirmed cases, 850 were in the placebo group while just 77 were in the vaccinated group.

The vaccine also proved fully protective against severe disease as defined by the Centers for Disease Control and Prevention (CDC). A single severe case, according to the FDA’s definition, was seen in the vaccine group, indicating a 95.3 percent efficacy against severe COVID-19. The FDA’s definition of severe COVID-19 includes an increased respiratory rate of 30 breaths or more per minute, an increased heart rate of 125 beats or more per minute and oxygen saturation levels of 93 percent or lower.

Additionally, the trial saw only nine cases of COVID-19 out of its 800 participants in South Africa, where a concerning viral mutation has spread and has raised fears it could evade vaccine protection. The nine cases were all in the placebo group, indicating the vaccine demonstrated 100 percent efficacy against the South Africa strain.

The companies said they have also collected safety data from more than 12,000 vaccinated participants with at least six months of follow-up and seen favorable safety and tolerability for the vaccine, with no serious safety concerns identified. They now have the data they need to file for full approval and plan to submit it for peer review and potential publication “in the near future.”

In additional good news, a real-world study of the vaccine led by the UK’s University of Birmingham found that two doses generated strong immune responses in elderly patients. Specifically, of the 100 patients age 80 to 96 years, 98 percent of them showed a strong antibody immune response. The vaccine took a hit against the virus’ Brazilian mutation, but still appeared to likely provide adequate protection. — James Miessler

COVID-19

Upcoming Events

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

  • 06May

    The World of Post-COVID-19 Clinical Trials: How to Prepare for What’s Coming Next

  • 12May

    Extractables and Leachables: 101

  • 19May

    CDRH’s New Accreditation Scheme for Conformity Assessment: Impacts on Your Future Testing Plans and FDA Submissions

  • 25May

    How Can the Accelerated Availability of Pfizer-BioNTech’s COVID-19 Vaccine be Replicated?

  • 27May

    Evolving Clinical Trials: Continuing the Journey from Paper to Digital

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Fujifilm_Logo.gif

    Fujifilm Begins Late-Stage Trial of Avigan for COVID-19

  • CE mark

    DiaSorin’s 10-Minute COVID-19 Antibody Test CE Marked

  • WHO

    WHO Will Review Two COVID-19 Vaccines from China

  • CE mark

    Qiagen’s High Throughput COVID-19 Test Earns CE Mark

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing